Skip to main content

Table 1 Association of DOT1L expression with the clinicopathological features of patients with borderline and malignant ovarian tumors

From: Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer

Characteristics

Sample

DOT1L expression

χ 2

P

  

Low expression

High expression

  

Age at diagnosis

235

  

0.120

0.729

 ≤50

114

51 (44.7%)

63 (55.3%)

  

 >50

117

55 (47.0%)

62 (53.0%)

  

 Unknown

4

    

FIGO stage

235

  

17.655

0.001

 I

20

18 (90.0%)

2 (10.0%)

  

 II

17

8 (47.1%)

9 (52.9%)

  

 III

159

66 (41.5%)

93 (58.5%)

  

 IV

29

11 (37.9%)

18 (62.1%)

  

 Unknown

10

    

Histologic grade

235

  

8.831

0.012

 Grade 1

40

27 (67.5%)

13 (32.5%)

  

 Grade 2

58

24 (41.4%)

34 (58.6%)

  

 Grade 3

120

50 (41.7%)

70 (58.3%)

  

 Unknown

17

    

Ascites

235

  

0.005

0.944

 Yes

173

78 (45.1%)

95 (54.9%)

  

 No

36

16 (44.4%)

20 (55.6%)

  

 Unknown

26

    

LN metastasis

235

  

4.392

0.036

 Yes

73

29 (39.7%)

44 (60.3%)

  

 No

106

59 (55.7%)

47 (44.3%)

  

 Unknown

56

    

Preoperative CA125 (U/ml)

235

  

1.829

0.176

 ≤600

68

33 (48.5%)

35 (51.5%)

  

 >600

80

30 (37.5%)

50 (62.5%)

  

 Unknown

87

   Â